LEQEMBI is indicated for use in adults with mild cognitive impairment or mild Alzheimer’s disease (AD). Credit: fizkes / ...

Dimerix will retain all commercialisation rights for DMX-200 in all other unlicensed territories for treating FSGS kidney ...

Dr. Reddy's Laboratories' Russian subsidiary and Novartis Pharma signed a deal for the distribution of anti-diabetes products ...

Eli Lilly has annaounced a $5.3bn investment at its site in Lebanon, Indiana, US, to enhance API manufacturing capacity.

MSD licenced the antibody-drug conjugate (ADC) therapy, sacituzumab tirumotecan, from China-based Sichuan Kelun-Biotech in ...

The European Commission (EC) has approved Celltrion ’s Omlyclo (CT-P39) - the first and only omalizumab biosimilar for ...

The US FDA's EMDAC is set to hold a meeting to assess the benefit-risk profile of Novo Nordisk's insulin icodec, to treat ...

Shares in Merus rose by 15% in premarket trading, following the announcement of positive Phase II data to be presented at ...

Biocon has entered an exclusive licence and supply agreement with Handok to commercialise synthetic Liraglutide in South ...

The US Food and Drug Administration (FDA) has granted Roche a breakthrough therapy designation for its breast cancer therapy ...

AstraZeneca is set to invest $1.5bn in a new manufacturing facility in Singapore dedicated to the production of antibody drug ...

AstraZeneca has entered into a worldwide licence and option agreement with Nona Biosciences for a preclinical monoclonal ...